- For Print
- April 24, 2024
吃瓜大赛黑料头条 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “吃瓜大赛黑料头条”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).
This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). 吃瓜大赛黑料头条’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in 吃瓜大赛黑料头条's financial disclosure scheduled on May 15, 2024.
吃瓜大赛黑料头条 serves as the lead of lecanemab development and regulatory submissions globally with both 吃瓜大赛黑料头条 and Biogen Inc. co-commercializing and co-promoting the product and 吃瓜大赛黑料头条 having final decision-making authority.
&苍产蝉辫;銆赌
&苍产蝉辫;銆赌
Media Inquiries:
Public Relations Department,
吃瓜大赛黑料头条 Co., Ltd.
+81-(0)3-3817-5120
&苍产蝉辫;銆赌銆�